WO2000062793A3 - Pseudomycin antifungal compositions and methods for their use - Google Patents

Pseudomycin antifungal compositions and methods for their use Download PDF

Info

Publication number
WO2000062793A3
WO2000062793A3 PCT/US2000/008725 US0008725W WO0062793A3 WO 2000062793 A3 WO2000062793 A3 WO 2000062793A3 US 0008725 W US0008725 W US 0008725W WO 0062793 A3 WO0062793 A3 WO 0062793A3
Authority
WO
WIPO (PCT)
Prior art keywords
pseudomycin
methods
compositions
antifungal compositions
antifungal
Prior art date
Application number
PCT/US2000/008725
Other languages
French (fr)
Other versions
WO2000062793A2 (en
Inventor
Venkatraghavan Vasudevan
Thomas Warren Jones
Michael John Rodriguez
Stephanie Ann Sweetana
Original Assignee
Lilly Co Eli
Venkatraghavan Vasudevan
Thomas Warren Jones
Michael John Rodriguez
Stephanie Ann Sweetana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Venkatraghavan Vasudevan, Thomas Warren Jones, Michael John Rodriguez, Stephanie Ann Sweetana filed Critical Lilly Co Eli
Priority to AU43287/00A priority Critical patent/AU4328700A/en
Priority to CA002371942A priority patent/CA2371942A1/en
Priority to MXPA01010247A priority patent/MXPA01010247A/en
Priority to EA200101088A priority patent/EA200101088A1/en
Priority to EP00923108A priority patent/EP1171150A2/en
Priority to JP2000611929A priority patent/JP2002542201A/en
Priority to BR0009778-0A priority patent/BR0009778A/en
Publication of WO2000062793A2 publication Critical patent/WO2000062793A2/en
Publication of WO2000062793A3 publication Critical patent/WO2000062793A3/en
Priority to NO20014988A priority patent/NO20014988L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

Methods and compositions for treating fungal infections that include formulations of a pseudomycin or related antifungal agent and a cyclodextrin are described. The compositions are particularly useful in pharmaceutical applications to reduce adverse effects.
PCT/US2000/008725 1999-04-15 2000-04-14 Pseudomycin antifungal compositions and methods for their use WO2000062793A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU43287/00A AU4328700A (en) 1999-04-15 2000-04-14 Pseudomycin antifungal compositions and methods for their use
CA002371942A CA2371942A1 (en) 1999-04-15 2000-04-14 Pseudomycin antifungal compositions and methods for their use
MXPA01010247A MXPA01010247A (en) 1999-04-15 2000-04-14 Pseudomycin antifungal compositions and methods for their use.
EA200101088A EA200101088A1 (en) 1999-04-15 2000-04-14 PREVENTION COMPOSITIONS OF PSEVDOMICINS AND METHODS OF THEIR APPLICATION
EP00923108A EP1171150A2 (en) 1999-04-15 2000-04-14 Pseudomycin antifungal compositions and methods for their use
JP2000611929A JP2002542201A (en) 1999-04-15 2000-04-14 Pseudomycin antifungal compositions and methods of use
BR0009778-0A BR0009778A (en) 1999-04-15 2000-04-14 Antifungal compositions of pseudomycin and methods for using them
NO20014988A NO20014988L (en) 1999-04-15 2001-10-12 Pseudomycin antifungal compositions and methods for their applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12943599P 1999-04-15 1999-04-15
US60/129,435 1999-04-15

Publications (2)

Publication Number Publication Date
WO2000062793A2 WO2000062793A2 (en) 2000-10-26
WO2000062793A3 true WO2000062793A3 (en) 2001-01-18

Family

ID=22439926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008725 WO2000062793A2 (en) 1999-04-15 2000-04-14 Pseudomycin antifungal compositions and methods for their use

Country Status (11)

Country Link
EP (1) EP1171150A2 (en)
JP (1) JP2002542201A (en)
CN (1) CN1360505A (en)
AU (1) AU4328700A (en)
BR (1) BR0009778A (en)
CA (1) CA2371942A1 (en)
EA (1) EA200101088A1 (en)
HU (1) HUP0201048A3 (en)
MX (1) MXPA01010247A (en)
NO (1) NO20014988L (en)
WO (1) WO2000062793A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
BRPI0105509B8 (en) * 2001-11-05 2021-05-25 Univ Minas Gerais formulations of the angiotensin- (1-7) peptide using cyclodextrins, liposomes and the plga polymer
DE10228049A1 (en) 2002-06-24 2004-01-15 Merck Patent Gmbh Liquid preparation containing oligopeptides
ES2378279T3 (en) 2006-06-29 2012-04-10 Arigen Pharmaceuticals, Inc. Agent intended to be used for an injection comprising antibiotic, and solution for injection comprising the agent
TWI568365B (en) * 2014-07-22 2017-02-01 蘇廷弘 Antibacterial composites and method for manufacturing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830855A (en) * 1996-09-12 1998-11-03 Utah State University Lipodepsipeptides as antifungal and fungicidal agents
US5837685A (en) * 1992-11-30 1998-11-17 Research And Development Institute Inc. At Montana State University Peptides from Pseudomonas syringae possessing broad-spectrum antibiotic activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837685A (en) * 1992-11-30 1998-11-17 Research And Development Institute Inc. At Montana State University Peptides from Pseudomonas syringae possessing broad-spectrum antibiotic activity
US5830855A (en) * 1996-09-12 1998-11-03 Utah State University Lipodepsipeptides as antifungal and fungicidal agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JARVINEN TOMI ET AL: "Sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits.", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 11, no. 2, 1995, pages 95 - 106, XP000953392, ISSN: 1080-7683 *
SORENSEN KEVIN N ET AL: "In vitro antifungal and fungicidal activities and erythrocyte toxicities of cyclic lipodepsinonapeptides produced by Pseudomonas syringae pv. syringae.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 40, no. 12, 1996, pages 2710 - 2713, XP002152672, ISSN: 0066-4804 *
SZEJTLI J: "Medicinal applications of cyclodextrins.", MEDICINAL RESEARCH REVIEWS, vol. 14, no. 3, 1994, pages 353 - 386, XP000953349, ISSN: 0198-6325 *

Also Published As

Publication number Publication date
CN1360505A (en) 2002-07-24
MXPA01010247A (en) 2002-03-27
WO2000062793A2 (en) 2000-10-26
NO20014988L (en) 2001-12-03
AU4328700A (en) 2000-11-02
HUP0201048A2 (en) 2002-08-28
CA2371942A1 (en) 2000-10-26
BR0009778A (en) 2002-01-02
HUP0201048A3 (en) 2002-10-28
NO20014988D0 (en) 2001-10-12
EA200101088A1 (en) 2002-04-25
EP1171150A2 (en) 2002-01-16
JP2002542201A (en) 2002-12-10

Similar Documents

Publication Publication Date Title
WO2001045647A3 (en) Method for tabletting thickening systems
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2002076404A3 (en) Fatty alcohol drug conjugates
CA2233108A1 (en) Complex of y-cyclodextrin and retinol or retinol derivatives, processes for their preparation and their use
AU7645701A (en) Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides
AU2001290257A2 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU2001290257A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
WO2001058412A3 (en) Extracts from residues left in the production of wine
AU1211302A (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
AU2001236457A1 (en) Compounds and compositions for delivering active agents
WO2003015809A3 (en) Antimicrobial cationic peptides and formulations thereof
AU2557800A (en) Preservative compounds and compositions
IL155937A0 (en) Imidazole and benzimidazole derivatives and pharmaceutical compositions containing the same
AU2001288277A1 (en) Compounds and compositions for delivering active agents
WO2003066597A3 (en) Guanidino compounds
WO2002043706A3 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
WO2002028860A3 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
WO2003053180A3 (en) Undergarments containing active substances
AU2001286242A1 (en) Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
HUP0301506A3 (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
AU2002247726A1 (en) 2-Thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
WO2000062793A3 (en) Pseudomycin antifungal compositions and methods for their use
CA2402708A1 (en) Torasemide-containing pharmaceutical preparations
WO2002000208A3 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00806261.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010247

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2371942

Country of ref document: CA

Ref document number: 2371942

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 611929

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000923108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200101088

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2000923108

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000923108

Country of ref document: EP